Hey, Zoli!
I believe that is what I said. It will only
Hey, Zoli!
I believe that is what I said. It will only be if ALL of those things fail that they will care about the SP... because that will mean there is no cash, and they have to try to raise funds with stock, as it would be the only remaining option.
If one or more of these projects start to raise cash, they will not have to worry about the SP, because it won't be a source of raising capital. But the SP would presumably improve as well.
2
Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Crossing Continents for Women's Healing When Chelsey Goodan, an American expert in adolescent education, made her way to Hangzhou, China, it wasn't just another stop on her world tour. No, this was her first venture into China, rallying with Zhang Xinyuan, the brains behind Vimi Wellness. For those not in the know, Vimi's been pioneering women's intimate health and...
Continue Reading
UK Government Faces Job Data Reliability Crisis The UK government has recently identified a pressing challenge in acquiring dependable jobs data essential for effective economic policy-making. This issue has arisen due to flaws in the Labor Force Survey conducted by the Office for National Statistics (ONS), which is the main instrument used to gauge the UK job market. The...
Continue Reading
HII Announces Quarterly Cash Dividend HII (NYSE: HII) has made a significant declaration that is likely to resonate well with its shareholders. Recently, the company's Board of Directors confirmed a quarterly cash dividend of $1.35 per share to be distributed on June 13, 2025. This move underscores HII's ongoing commitment to its investors, as it rewards those holding...
Continue Reading
ZTE's Global Summit 2025: Shaping a Smarter Future in Milan Milan recently hosted a significant event as ZTE Corporation, a renowned leader in integrated information and communication technology solutions, gathered industry leaders from around the world. Under the theme "Expanding Intelligence, Creating Possibilities," the event focused on the crucial aspects of AI-driven...
Continue Reading
Dr. Stelios Papadopoulos Appointed to Ovid Therapeutics Board Ovid Therapeutics Inc. (NASDAQ: OVID), an innovative biopharmaceutical company, has made headlines with the announcement of Dr. Stelios Papadopoulos joining its Board of Directors. Known for his remarkable contributions to biotechnology, Dr. Papadopoulos brings with him a wealth of experience that promises to...
Continue Reading
